Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Friday that it has obtained Marketing Authorization in Denmark for Palbociclib Newbury tablets, marking the first approval within a Scandinavian registration procedure.
Approvals in Sweden and Norway are expected following completion of national regulatory reviews.
A generic version of Ibrance, Palbociclib Newbury is a selective CDK4 and CDK6 inhibitor indicated for the treatment of HR-positive and HER2-negative breast cancer. The Scandinavian market for the product is estimated at EUR21m annually, according to DLMI Nordic Pharma Insights.
Newbury plans to launch the product in relevant markets once regulatory exclusivities and patent constraints allow.
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
Dexcel Pharma's Nintedanib Capsules approved for US launch
Upsher-Smith launches generic version of Ciprodex ear drop suspension